Related Experiment Video
Updated: Nov 20, 2025
12:09
Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection
Published on: May 2, 2011
43.2K
Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera
Pei-Yong Shi1, Xuping Xie2, Jing Zou2
1The University of Texas Medical Branch at Galveston.
Research Square
|January 20, 2021
Abstract:
Rapidly spreading variants of SARS-CoV-2 that have arisen in the United Kingdom and South Africa share the spike N501Y substitution, which is of particular concern because it is located in the viral receptor binding site for cell entry and increases binding to the receptor. We generated isogenic N501 and Y501 SARS-CoV-2. Twenty human sera from the mRNA-based vaccine BNT162b2 trial exhibited equivalent neutralizing titers to the N501 and Y501 viruses.
